WO1995004533A3 - Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents - Google Patents

Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents Download PDF

Info

Publication number
WO1995004533A3
WO1995004533A3 PCT/US1994/008742 US9408742W WO9504533A3 WO 1995004533 A3 WO1995004533 A3 WO 1995004533A3 US 9408742 W US9408742 W US 9408742W WO 9504533 A3 WO9504533 A3 WO 9504533A3
Authority
WO
WIPO (PCT)
Prior art keywords
thalidomide
rheumatoid arthritis
steroidal
combination
relates
Prior art date
Application number
PCT/US1994/008742
Other languages
French (fr)
Other versions
WO1995004533A2 (en
Inventor
Peter J Andrulis Jr
Original Assignee
Andrulis Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrulis Pharm Corp filed Critical Andrulis Pharm Corp
Priority to AU73764/94A priority Critical patent/AU7376494A/en
Publication of WO1995004533A2 publication Critical patent/WO1995004533A2/en
Publication of WO1995004533A3 publication Critical patent/WO1995004533A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin

Abstract

The present invention relates to a novel method for treating rheumatoid arthritis with thalidomide alone or in combination with anti-rheumatoid agents and/or with steroidal and/or non-steroidal anti-inflammatory drugs. The present invention also relates to methods of treating rheumatoid arthritis with tumor necrosis factor inhibitors as well as pharmaceutical compositions containing tumor necrosis factor inhibitors and steroidal and/or non-steroidal anti-inflammatory and/or anti-rheumatoid drugs. A further aspect of this invention relates to a special pharmaceutical composition containing thalidomide wherein said thalidomide has been micronized to a particle size of less than 1.0 microns. Compositions containing such micronized thalidomide exhibit faster absorption rates than previously known thalidomide formulations.
PCT/US1994/008742 1993-08-04 1994-08-03 Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents WO1995004533A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU73764/94A AU7376494A (en) 1993-08-04 1994-08-03 Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10172493A 1993-08-04 1993-08-04
US08/101,724 1993-08-04

Publications (2)

Publication Number Publication Date
WO1995004533A2 WO1995004533A2 (en) 1995-02-16
WO1995004533A3 true WO1995004533A3 (en) 1995-04-27

Family

ID=22286074

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/008742 WO1995004533A2 (en) 1993-08-04 1994-08-03 Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents

Country Status (2)

Country Link
AU (1) AU7376494A (en)
WO (1) WO1995004533A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6114355A (en) * 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US8143283B1 (en) 1993-03-01 2012-03-27 The Children's Medical Center Corporation Methods for treating blood-born tumors with thalidomide
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
IT1276031B1 (en) * 1995-10-31 1997-10-24 Angelini Ricerche Spa PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTOIMMUNE DISEASES
DK1586322T3 (en) * 1996-11-05 2008-12-01 Childrens Medical Center Compositions containing thalidomide and dextamethasone for the treatment of cancer
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
DE10230381A1 (en) * 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Use of inhibitors of alanyl aminopeptidases and pharmaceutical compositions comprising them
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
AU2009239429B2 (en) * 2008-04-21 2013-08-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
UY31779A (en) * 2008-04-21 2009-12-14 Univ California FORMULATIONS FOR THE EAR TO TREAT OPTICAL DISEASES AND CONDITIONS
EP2768594B1 (en) 2011-10-18 2023-06-07 The Trustees of Columbia University in the City of New York Medical apparatus and method for collecting biological samples
CN106138052B (en) * 2015-04-16 2020-02-21 欣凯医药化工中间体（上海）有限公司 Thalidomide preparation and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014455A1 (en) * 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014455A1 (en) * 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUTIERREZ-RODRIGUEZ, O. ET AL: "TREATMENT OF REFRACTORY RHEUMATOID ARTHRITIS-THE THALIDOMIDE EXPERIENCE", THE JOURNAL OF RHEUMATOLOGY, vol. 16, no. 2, 1989, pages 158 - 63 *
GUTIERREZ-RODRIGUEZ, O.: "THALIDOMIDE A PROMISING NEW TREATMENT FOR RHEUMATOID ARTHRITIS", ARTHRITIS AND RHEUMATISM, vol. 27, no. 10, October 1984 (1984-10-01), pages 1118 - 1121 *

Also Published As

Publication number Publication date
WO1995004533A2 (en) 1995-02-16
AU7376494A (en) 1995-02-28

Similar Documents

Publication Publication Date Title
WO1995004533A3 (en) Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
AU2732892A (en) Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
IE821453L (en) Oral dipyridamole preparations
AU3912493A (en) A pharmaceutical composition containing a defined lipid system
AU6027996A (en) Substituted sulfonylphenylheterocycles as cyclooxygenase-2 a nd 5-lipoxygenase inhibitors
AU2068995A (en) Inhalation composition containing lactose pellets
HU895286D0 (en) Process for the preparation of steroid 5alfa-reductase inhibiting compounds and pharmaceutical compositions containing such compounds
CA2109208A1 (en) Radiolabeled metal-binding protein for the treatment of arthritis
AU4187093A (en) 5,10-methylenetetrahydrofolic acid-cyclodextrin inclusion compounds
BG104596A (en) Pahrmaceutical compositions containing micronized bicyclic drugs
HU9401412D0 (en) Process for producing dry- processed particles, the produced dry-processed paricles, and pharmaceutical compositions containing them
RU94000064A (en) New 2-cyano-3-hydroxypropeneamides, method of preparing thereof, and pharmaceutical compositions containing said compounds
ITRM940322A0 (en) "PHARMACEUTICAL COMPOSITION CONTAINING CARBAZOLONE FOR THE TREATMENT OF MIGRAINE AND PSYCHOTIC DISORDERS AND RELATED METHOD OF PREPARATION AND APPLICATION".
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
AU3555793A (en) Pharmaceutical compositions for the treatment and/or prevention of degenerative disorders in the retina
MY111719A (en) Psoriasis treatment
AR004178A1 (en) PROCEDURE FOR THE FORMULATION OF A PHARMACY, A PHARMACEUTICAL COMPOSITION OBTAINABLE THROUGH THIS PROCEDURE AND THE USE OF THE SAME.
AU624739B2 (en) 3-substituted-2-oxindole derivatives as inhibitors of interleukin-1 biosynthesis
HUP9702408A3 (en) Use of 5-phenyloxazolidin-2-one derivatives for the preparation of pharmaceutical compositions treating diseases requiring tumour necrosis factor (tnf) inhibition
PL320996A1 (en) 4,4-(disubstituted) monomers of cyclohexan-1-ol and compounds shoving affinity to them
WO1996020690A3 (en) 3,3-(disubstituted)cyclohexan-1-ylidine acetate monomers and related compounds
GB8928609D0 (en) Pharmaceutical composition
AU5662996A (en) Compounds and compositions for delivering active agents
GR3024253T3 (en) High dose vitamin a compositions.
IL100889A (en) Nootropic and nerve- regenerative pharmaceutical compositions comprising 4-(7-bromo- 5-methoxybenzofuran-2-yl) piperidine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase